Marinus Pharmaceuticals (NASDAQ:MRNS) Upgraded by Zacks Investment Research to Buy

Marinus Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Marinus Pharmaceuticals Upgraded by Zacks Investment Research on 10/20/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

View More Marinus Pharmaceuticals (NASDAQ:MRNS) Upgraded by Zacks Investment Research to Buy